Chronic Inflammatory Demyelinating Polyneuropathy Market Research Updates and Clinical Trials In 2025

The Chronic inflammatory Demyelinating Polyneuropathy Market size reached US$ 2.02 Billion in 2024 and is expected to reach US$ 5.07 Billion by 2033, growing at a CAGR of 9.7% during the forecast period 2025-2033.

Chronic Inflammatory Demyelinating Polyneuropathy Market, as detailed in the DataM Intelligence report, presents a strategic overview of the industry backed by in-depth data and market trends. The study highlights the performance and positioning of major players, focusing on their offerings, pricing models, financial outcomes, and growth strategies. It serves as a concise yet insightful reference for understanding the current landscape and future direction of the market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/chronic-inflammatory-demyelinating-polyneuropathy-market?kb

Market Overview:

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder causing inflammation of peripheral nerves, leading to progressive weakness and sensory dysfunction. It often requires long-term immunotherapy to manage symptoms and improve quality of life.

List of the Key Players in the Chronic Inflammatory Demyelinating Polyneuropathy Market:

Bio Products Laboratory Ltd, Momenta Pharmaceuticals, Grifols, Baxter, Kedrion S.p.A, Octapharma, Shire, Mitsubishi Tanabe Pharma Corporation,CSL Behring, Teijin Pharma Limited and Pfizer, Inc.

Chronic Inflammatory Demyelinating Polyneuropathy Market Development:

In May 2024, Zai Lab Limited submitted a supplemental Biologics License Application (sBLA) to China's National Medical Products Administration (NMPA) for efgartigimod alfa injection (efgartigimod SC) aimed at treating chronic inflammatory demyelinating polyneuropathy (CIDP).

In June 2024, argenx SE announced that the U.S. Food and Drug Administration (FDA) approved VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for adult CIDP patients. This approval represents a major milestone as VYVGART Hytrulo becomes the first and only neonatal Fc receptor (FcRn) blocker authorized for CIDP treatment.

Additionally, in December 2023, Takeda revealed that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) had recommended HYQVIA for approval as a maintenance therapy for CIDP patients following stabilization with intravenous immunoglobulin (IVIG).

Speak to Our Senior Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/chronic-inflammatory-demyelinating-polyneuropathy-market?kb

Segment Covered in the Chronic Inflammatory Demyelinating Polyneuropathy Market:

By Treatment Type: Immunoglobulin Therapy, Corticosteroids , Immunosuppressants, Physical Therapy, Plasma Exchange

By Route of Administration: Oral, Intravenous

By End User: Hospitals, Speciality Clinics, Research and Academic Institutes

Regional Analysis for Chronic Inflammatory Demyelinating Polyneuropathy Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Frequently asked questions:

➠ What are the global sales, production, consumption, import, and export figures for the Chronic Inflammatory Demyelinating Polyneuropathy market?

➠ Who are the key global manufacturers, and how are they performing operationally?

➠ What opportunities and risks do vendors face in the Chronic Inflammatory Demyelinating Polyneuropathy market?

➠ Which product types or end-users show the most growth potential, and what are their market shares?

➠ What factors are driving or limiting growth in the Chronic Inflammatory Demyelinating Polyneuropathy market?

Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription?kb

Contact Us-

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us-

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.